Antheia Raises $73M in Series B Funding
- Antheia, a Menlo Parck CA-based synthetic biology company, raised $73M in Series B funding
- The round was led by Viking Global Investors with participation from Sherpalo Ventures and Hillspire
- The company intends to use the funds to expand its pipeline and scale production in global markets
- The company is a synthetic biology company enabling next-generation plant-inspired medicines through a novel whole-cell engineering approach to reconstruct complex molecules in yeast
- The funds will support the company to bring its first pharmaceutical compound to market and scale up the production of a number of APIs
- The platform can be applied to a wide range of pharmaceuticals that typically use plant-derived molecules
